◼ Archived
Business
Verastem CEO claims RAS drug has 'set a new benchmark' for tricky cancer in early readout
Verastem advances its experimental KRAS inhibitor to Phase III following positive early data and a major funding round.
4 trends tracked about this subject — the full history, oldest to newest below.
Verastem advances its experimental KRAS inhibitor to Phase III following positive early data and a major funding round.
Recent coverage examines how scientists cracked the RAS mutation in pancreatic cancer and explores Arizona connections to the breakthrough treatment.
The FDA has approved daraxonrasib for the treatment of previously treated RAS-mutant non-small-cell lung cancer and pancreatic cancer.
7 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.